undamentalytics Newsletter
Sign in

Biodesix Inc income statement

In fiscal 2025, Biodesix Inc reported revenue of $88.5m, up 24.1% on the year before, operating income of −$27.9m (a -31.5% margin) and net income of −$35.3m, or −$4.67 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue25465538497188103
Research and development1011131310101212
Selling, general and administrative3135516167808893
Operating income−27−23−41−51−41−34−28−21
Interest expense385810888
Provision for credit losses————0100
Income tax—0000000
Net income−31−65−43−65−52−43−35−28
Diluted EPS−$13789.96−$703.78−$15.80−$15.50−$0.64−$6.64−$4.67−$3.13
Diluted shares (average)—45m3m4m4m6m8m9m
EBITDA−24−20−38−47−38−29−22−15

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: BDSX vs MDXHBDSX vs HBIOBDSX vs CDXS

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Biodesix Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Biodesix Inc.